In December 2022, Johnson enrolled in an early-stage clinical trial at the Cleveland Clinic that is testing a novel vaccine ...
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the first ...
ROTTERDAM, the Netherlands, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Pan Cancer T B.V., a biotech company pioneering next-generation ...
BioNTech and Bristol Myers Squibb share positive data from Phase 2 trial of pumitamig plus chemotherapy for triple-negative ...
The addition of the immune checkpoint inhibitor Tecentriq (atezolizumab) to neoadjuvant chemotherapy and as a single agent ...
Dr Hope Rugo explores how new data suggest immunotherapy could reshape the standard of care for early-stage HR+ and ...
NEW ORLEANS - Researchers at the LSU LCMC Health Cancer Center have published groundbreaking findings in the medical journal ...
Kazia Therapeutics Limited ("Kazia" or the "Company") (NASDAQ: KZIA) today announced new data from two presentations at the 2025 San Antonio Breast Cancer Symposium (SABCS) providing compelling ...
Findings set the stage for further investigation of hSFRP2 mAb as a targeted therapy for triple-negative breast cancer.
At the San Antonio Breast Cancer Symposium (SABCS), investigators reported final phase I results of an alpha-lactalbumin (aLA ...
1don MSN
Breast cancer: Triple-negative breast cancer vaccine shows promise in phase 1 clinical trial
A new vaccine targeting triple-negative breast cancer (TNBC) has shown promising results in its first human clinical trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback